Vitamin D Effect on A Disintegrin-like And Metalloprotease Thrombospondin1 Motif 13& Interleukin 6 in Leukemia

• Status: Completed
• Trial end date: 2021-03-15
• Target enrollment: 0
• Participant gender: All

Summary

A Disintegrin-like And Metalloprotease with Thrombospondin type 1 motif 13 (ADAMTS13) deficiency was incriminated in poor prognosis, high probability of serious complications and mortality in acute myeloid leukemia (AML) patients. Interleukin 6 (IL-6) produced from AML blasts decreases Cluster of differentiation 34 positive(CD34+) cells differentiation, and inhibits the ADAMTS13 actions. Vitamin D "as an Immune-modulator" inhibits the pro-inflammatory cytokines including IL-6. So, supplementation of vitamin D might help down regulation of interleukin-6 production.

Aim of the study To evaluate the potential relation between Vitamin D status, ADAMTS13 and IL-6 in AML patients.

Objectives

1. Assess Vitamin D level in AML patients

2. Assess ADAMTS13 and IL-6 in AML patients

3. Correlate between Vitamin D level and both of ADAMTS13 and IL-6

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Zagazig University
• Treatments: Cholecalciferol

Criteria

Inclusion Criteria:

1. Patient's consent to share in the study

2. Patients' age >18 years

3. Patients with denovo acute myeloid leukemia

Exclusion Criteria:

1. Patients refusing to share in the study

2. Non-Egyptian patients

3. Patients' age < 18 years

4. Pregnant women

5. Patient's with other malignancies

6. Patients with known congenital thrombotic/ hemorrhagic diseases

7. Patients with Thrombotic Thrombocytopenic Purpura

8. Patients with auto-immune diseases